Dipartimento di Reumatologia, Struttura Complessa di Reumatologia DH, Istituto ortopedico G. Pini, Milano, Italy.
Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S15-27. Epub 2011 Aug 29.
Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations, and, to this end, a systematic literature review was performed and the evidence derived from it was discussed and summarized as expert opinions. Levels of evidence and strength of recommendations were reported. The recommendations reported refer to the safety of biologic agents and are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.
鉴于新型生物制剂可用于治疗类风湿关节炎（rheumatoid arthritis，RA），为协助风湿病学家开具这些药物，各个国家的科学学会制定了具体建议。意大利风湿病学会（Società Italiana di Reumatologia，SIR）决定更新其建议，为此进行了系统文献复习，并对从中获得的证据进行了讨论和总结，形成专家意见。报告了证据水平和推荐强度。报告的建议涉及生物制剂的安全性，旨在帮助开具处方的风湿病学家优化在日常实践中治疗 RA 患者时使用生物制剂；不应将这些建议视为监管规则。
